J
Jeffrey S. Morris
Researcher at University of Pennsylvania
Publications - 212
Citations - 13000
Jeffrey S. Morris is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 49, co-authored 207 publications receiving 10519 citations. Previous affiliations of Jeffrey S. Morris include University of Texas Health Science Center at Houston & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
The consensus molecular subtypes of colorectal cancer
Justin Guinney,Rodrigo Dienstmann,Rodrigo Dienstmann,Xingwu Wang,Xingwu Wang,Aurélien de Reyniès,Andreas Schlicker,Charlotte Soneson,Laetitia Marisa,Paul Roepman,Gift Nyamundanda,Paolo Angelino,Brian M. Bot,Jeffrey S. Morris,Iris Simon,Sarah Gerster,Evelyn Fessler,Felipe De Sousa E Melo,Edoardo Missiaglia,Hena R. Ramay,David Barras,Krisztian Homicsko,Dipen M. Maru,Ganiraju C. Manyam,Bradley M. Broom,Valérie Boige,Beatriz Perez-Villamil,Ted Laderas,Ramon Salazar,Joe W. Gray,Douglas Hanahan,Josep Tabernero,René Bernards,Stephen H. Friend,Pierre Laurent-Puig,Jan Paul Medema,Anguraj Sadanandam,Lodewyk F. A. Wessels,Mauro Delorenzi,Mauro Delorenzi,Scott Kopetz,Louis Vermeulen,Sabine Tejpar +42 more
TL;DR: An international consortium dedicated to large-scale data sharing and analytics across expert groups is formed, showing marked interconnectivity between six independent classification systems coalescing into four consensus molecular subtypes (CMSs) with distinguishing features.
Journal ArticleDOI
Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments
TL;DR: Concerns suggest that much of the structure uncovered in SELDI proteomic spectra from serum experiments could be due to artifacts of sample processing, not to the underlying biology of cancer.
Journal ArticleDOI
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
Scott Kopetz,Paulo M. Hoff,Jeffrey S. Morris,Robert A. Wolff,Cathy Eng,Katrina Y. Glover,Rosie Adinin,Michael J. Overman,Vincete Valero,Sijin Wen,Christopher H. Lieu,Shaoyu Yan,Hai T. Tran,Lee M. Ellis,James L. Abbruzzese,John V. Heymach +15 more
TL;DR: Efficacy and tolerability of FOLFIRI + B appeared favorable to historical controls in this single arm study, and there was a shift in balance of CAFs, with a rise in alternate pro-angiogenic cytokines and myeloid recruitment factors in subsets of patients that may represent mechanisms of resistance.
Journal ArticleDOI
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation
Lucian R. Chirieac,Stephen G. Swisher,Jaffer A. Ajani,Ritsuko Komaki,Arlene M. Correa,Jeffrey S. Morris,Jack A. Roth,Asif Rashid,Stanley R. Hamilton,Tsung-Teh Wu M.D. +9 more
TL;DR: In patients with locoregional carcinoma of the esophagus or esophagogastric junction who underwent preoperative chemoradiation, it is unclear whether survival was better predicted by pretherapy clinical stage or by posttherapy pathologic stage.
Journal ArticleDOI
Body Mass Index and Risk, Age of Onset, and Survival in Patients With Pancreatic Cancer
Donghui Li,Jeffrey S. Morris,Jun Liu,Manal M. Hassan,R. Sue Day,Melissa L. Bondy,James L. Abbruzzese +6 more
TL;DR: Overweight or obesity during early adulthood was associated with a greater risk of pancreatic cancer and a younger age of disease onset and obesity at an older age was associatedWith a lower overall survival in patients with Pancreatic cancer.